A Phase 3 interventional study of Rejeunesse and Restylane Perlane in Nasolabial Fold Correction, sponsored by Forest Hills Lab. Completed. Open to participants aged 30 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-08-18.
Sponsored by Forest Hills Lab · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Intend to prove the non-inferiority of Rejeunesse against the comparing medical device of Restylane Perlane in terms of improvement, efficacy, and safety of nasolabial fold on the face
Forest Hills Lab is the lead sponsor of 3 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Device: Rejeunesse
Device: Restylane Perlane
The clinical medical device, Rejeunesse, is a cross-lined HA hydrogel made by using the cross-linker of 1, 4-butandiol diglycidyl ether (BDDE) with low toxicity from sodium hyaluronate derived from microorganisms. It is a tissue repair biological material in a gel type injected to the skin (thick skin - epidermis and surface of thick skin) near wrinkles on the face for the temporary improvement of wrinkles.
Restylane Perlane selected as the control group is non-animal stabilized hyaluronic acid (NASHA) originating from bacterial fermentation. It is a tissue repair biomaterial for soft skin \[3\]. Restylane Perlane is widely used for wrinkle treatment, indented areas and other beauty purposes. Products used in this clinical study can be applied to all types of wrinkles on the face. Stabilized HA constituting the Restylane Perlane is slowly absorbed in the body after combining with water molecules in the skin tissue and is completely absorbed in the skin as a biodegradable substance. Therefore, no residue is left in the body.
Primary Endpoint Variables
Verify the average value of the difference between Wrinkle Severity Rating Scale (WSRS) between control group and experiment group assessed by the independent evaluator on the 24th week after the final application of medical devices for clinical study Compare the average value of WSRS between control group and experiment group assessed by the independent evaluator on the 24th week after the final application of clinical medical devices. The WSRS is a 5 point scale with 1 being no wrinkles and 5 being extreme wrinkles.
Time frame: 24th week after the final application of medical devices for clinical study and assess WSRS.
Average value of Visual Analogue Scale (VAS) between the experiment group and control group within 60 minutes after the final application of clinical medical devices.
Make sure to evaluate the degree of pain on a scale from 0 to 10 that subjects feel in the operation when applying or immediately after applying the clinical medical devices. The Visual Analogue Scale (VAS) is the record of the severest pain on the one side while recording that there is no pain on the other side in the 10cm length of line. 0 is "no pain" and 10 is worst pain possible.
Time frame: 60 minutes after the final application of clinical medical devices
Average value of Wrinkle Severity Rating Scale (WSRS) between the experiment group and control group on the 8th week after the final application of clinical medical devices.
Compare the Wrinkle Severity Rating Scale (WSRS) average value between experiment group and control group assessed by the independent evaluator on the 8th week after the final application of clinical medical devices. The WSRS is a 5 point scale with 1 being no wrinkles and 5 being extreme wrinkles.
Time frame: 8th week after the final application of clinical medical devices
Average value of global aesthetic improvement scale (GAIS) between control and experiment group assessed by the investigators on the 8th and 24th week after the final application of medical devices before the initial application of medical devices
Compare the average value of GAIS assessed by each investigator on the 8th and 24th week after the final application compared to before the initial application of clinical medical devices
Time frame: 8th and 24th week after the final application of medical devices before the initial application of medical devices.
Average value of Global Aesthetic Improvement Scale (GAIS) between control group and experiment group assessed by the investigators on the 8th and 24th week after the final application of medical devices before the initial application of medical devices
Compare the average value of Global Aesthetic Improvement Scale (GAIS) assessed by each investigator on the 8th and 24th week after the final application compared to before the initial application of clinical medical devices. The Global Aesthetic Improvement Scale is a 5 point scale that goes from -1: worse, 0: no change, 1: improved, 2: much improved and 3: very much improved.
Time frame: 8th and 24th week after the final application compared to before the initial application of clinical medical devices
Proportion of changes in wrinkle severity rating scale (WSRS) between control group and experiment group on the 24th week after the final application of medical devices compared to before the initial application of medical devices
Compare the control group and experiment group in terms of proportion of WSRS changes assessed by the independent evaluator on the 24th week after the final application compared to before the initial application of clinical medical devices.
Time frame: 24th week after the final application compared to before the initial application of clinical medical devices.
Proportion of changes in wrinkle severity rating scale (WSRS) in the experiment group and control group on the 24'h week after the final application of medical devices prior to the initial application of medical devices assessed by the investigator.
Compare the control group and experiment group on the changes in WSRS value assessed by the investigator on the 24th week after the application in comparison to before the initial application of clinical medical devices
Time frame: 24th week after the application in comparison to before the initial application of clinical medical devices
No study locations are listed for this record.
Plan to share: No
No publications or documents are linked to this record.
Ran from Feb 2016 to primary completion in Sep 2016, 6 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.